2023-07-03 02:44:56
Photo = Yuhan Corporation
[인포스탁데일리=신민재 기자] Yuhan’s non-small cell lung cancer drug ‘Rexraza’ is gaining approval from the Ministry of Food and Drug Safety for first-line treatment in Korea, and its share price is rising.
At the same time, we raised our investment rating to ‘buy’ and the target price to 100,000 won. In our target price, we reflected the possibility of reimbursement following the approval of the first-line treatment in our earnings estimates.
With the approval of the first-line treatment, the possibility of insurance coverage has also increased.
Park Byeong-guk, a researcher at NH Investment & Securities, said, “As Tagrisso, a third-generation tyrosine kinase inhibitor (TKI), passed the deliberation of the Cancer Disease Review Board as a first-line treatment last March, the possibility of Relexa’s first-line listing has also increased.”
Currently, the size of the domestic primary benefit market for first- and second-generation TKIs, which are listed as first-line treatments, is estimated to be around 90 billion won.
Analysts say that if the third-generation drugs, Lexraza and Tagrisso, are listed on insurance coverage, the size of the first-line treatment market can grow significantly.
Yuhan Corporation’s main drug pipeline status. Source = Korea Investment & Securities
Researcher Park Byeong-guk said, “If the third-generation Tagrisso and Lekraza are listed, the treatment period will be doubled and the drug price will be 6 times higher than the 1st and 2nd generation TKIs, so the potential market size can grow up to 12 times.” judged
The market share (M/S) in the domestic primary treatment market is estimated at ▲40% for Tagrisso ▲40% for Lexraza and ▲20% for other 1st and 2nd generation TKi.
“Thus, in 2028, Lexraza’s primary treatment sales are estimated at 216 billion won,” he said. is estimated,” he said.
Yuhan Corporation stock price trend. Source = Naver
Reporter Shin Min-jae [email protected]
© Infostock Daily Unauthorized reproduction and redistribution prohibited
1688355546
#Yuhan #Corporations #firstline #treatment #Lexraza.. #Raise #target #price #won